| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.32 | 1e-10 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-06 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-06 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 5e-06 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.17 | 6e-06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.23 | 1e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 1e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.23 | 4e-05 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |